Arecor Limited (“Arecor” or “the Company”), the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology, ArestatTM to develop superior treatments for a range of disease areas, including diabetes, today announces that it has signed a collaboration with a new major global pharmaceutical partner.
Under the collaboration, Arecor will leverage its ArestatTM technology to develop superior liquid formulations of its partner’s proprietary products. The partner will fund the development work and has the option to acquire the rights to the formulation and…
Study compares two in vitro liver methods to determine which one best predicts BDIs
Westbury, NY – May 2, 2019 – BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that its ADME-Tox team has co-authored a second peer-reviewed paper investigating the potential for clinically-relevant botanical-drug interactions (BDIs) with toxicology colleagues at The Procter & Gamble Company (P&G).1 The paper describes a research collaboration by BioIVT and P&G based on studies conducted in BioIVT’s laboratory in Durham, NC.
This new…
30 April 2019
Collaboration with BenevolentAI will use machine learning and artificial intelligence to discover potential new drugs for chronic kidney disease and idiopathic pulmonary fibrosis
AstraZeneca and BenevolentAI today began a long-term collaboration to use artificial intelligence (AI) and machine learning for the discovery and development of new treatments for chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF).
Scientists from the two organisations will work side-by-side to combine AstraZeneca’s genomics, chemistry and clinical data with…
NEW YORK, NY & LONDON, UK, April 30th 2019 (Newswire) -- Alpha MD, a London-based global leader in healthcare research analytics and consulting, and Liberate Ideas, Inc. the leading provider of digital patient education for physicians, announce today a partnership agreement in order to initiate integration of Liberate Health in the UK’s National Health Service(NHS).
Liberate Health is a fast-growing healthcare professional digital patient education platform that has been proven to increase the effectiveness of the education encounter and, more importantly, reduce the time required by the…
AMSBIO reports on how several leading European research groups have used their Lipidure® coated microplates to help culture physiologically functional, light-responsive retinal organoids.Development of in vitro models of the human retina in which to perform pharmacological and toxicological studies is an urgent area of vital research. An essential step for developing in vitro models of human retina is the ability to generate laminated, physiologically functional, and light responsive retinal organoids from renewable and patient-specific sources.Professor Majlinda Lako from the Institute for…
AMSBIO reports on how several leading European research groups have used their Lipidure® coated microplates to help culture physiologically functional, light-responsive retinal organoids.Development of in vitro models of the human retina in which to perform pharmacological and toxicological studies is an urgent area of vital research. An essential step for developing in vitro models of human retina is the ability to generate laminated, physiologically functional, and light responsive retinal organoids from renewable and patient-specific sources.Professor Majlinda Lako from the Institute for…
Cambridge, UK, 30th April: PolyProx Therapeutics, a new biotechnology company focused on the discovery and development of novel biopharmaceuticals for the treatment of cancer, today announced that it has raised £3.4m of seed capital.
A spin out of the Department of Pharmacology at the University of Cambridge, PolyProx Therapeutics is based on over a decade of research and intellectual property from Founder, Professor Laura Itzhaki’s laboratory. Professor Itzhaki is joined at PolyProx Therapeutics by serial Cambridge biotech entrepreneurs Kevin Moulder as Chief Operating Officer and Andrew…
Do you as a company with a brilliant idea to solve a healthcare issue need to hire a Chief Medical Officer(CMO) at an early stage of your development?
The answer is NO, a perspective
Lets look at a typical job responsibility of a CMO
To perform this job successfully, an individual must be able to perform the following:
1) Direct the development of clinical strategies and plan to integrate compounds into the standard practice of the subject indication sometimes 2 or 3 indications.
2) Orchestrate and manage clinical aspects of regulatory strategies and interactions with Health Authorities.
3)…
InVisionFirst®-Lung demonstrated excellent concordance with tissue profiling and detected 26% more actionable alterations thanstandard-of-care testing
Data from two prospective U.S. trials published in Journal Clinical Oncology – Precision Oncology
Research Triangle Park, NC and Cambridge, UK, April 26, 2019 -- Inivata, a leader in liquid biopsy, today published the clinical validation results and real-world utility of its InVisionFirst-Lung liquid biopsy test for use in advanced non-small cell lung cancer (NSCLC). Inivata conducted two prospective, multi-center studies in…